Win Advisors’s Gilead Sciences GILD Stock Holding History

Win Advisors’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-102	Closed	-$6K	–	137
2022 Q2	$6K	Buy	102 +45	+79%	+$2.79K	0.01%	133
2022 Q1	$3K	Buy	+57	New	+$3.64K	﹤0.01%	167

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Win Advisors's GILD Position: Q3 2022 in Review

Win Advisors sold out of Gilead Sciences (GILD) in Q3 2022, closing a stake of 102 shares — an estimated $6K sold.

Win Advisors first reported a position in GILD in Q1 2022 and held it in 2 quarters. The position peaked at $6K in Q2 2022. 1,602 funds tracked by Wall St. Rank hold GILD as of Q3 2022.

Win Advisors reported no remaining Gilead Sciences position as of Q3 2022 after selling out during the quarter.
Win Advisors sold 102 Gilead Sciences shares in Q3 2022, an estimated $6K.
Win Advisors first reported a position in Gilead Sciences in Q1 2022 and held it in 2 quarters.
Win Advisors's Gilead Sciences position peaked at $6K in Q2 2022.
1,602 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2022.

Based on Win Advisors's 13F filing for Q3 2022, filed 27 Oct 2022.